NCT05404906View on ClinicalTrials.gov

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

June 25, 2022

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2030

Conditions
Acute Myeloid Leukemia (AML) in Remission
Interventions
DRUG

Azacitidine

Given SC

DRUG

Venetoclax

Given PO

OTHER

Supportive care

Patients will receive disease monitoring and supportive care for any complication.

Trial Locations (2)

215000

RECRUITING

First Affiliated Hospital of Soochow University, Suzhou

RECRUITING

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER